Peptides as multifunctional players in cancer therapy

SMP Vadevoo, S Gurung, HS Lee… - … & Molecular Medicine, 2023 - nature.com
Peptides exhibit lower affinity and a shorter half-life in the body than antibodies. Conversely,
peptides demonstrate higher efficiency in tissue penetration and cell internalization than …

Current state of breast cancer diagnosis, treatment, and theranostics

A Bhushan, A Gonsalves, JU Menon - Pharmaceutics, 2021 - mdpi.com
Breast cancer is one of the leading causes of cancer-related morbidity and mortality in
women worldwide. Early diagnosis and effective treatment of all types of cancers are crucial …

Targeting breast cancer: An overlook on current strategies

D Iacopetta, J Ceramella, N Baldino… - International Journal of …, 2023 - mdpi.com
Breast cancer (BC) is one of the most widely diagnosed cancers and a leading cause of
cancer death among women worldwide. Globally, BC is the second most frequent cancer …

The relationship between bone and reproductive hormones beyond estrogens and androgens

EG Mills, L Yang, MF Nielsen, M Kassem… - Endocrine …, 2021 - academic.oup.com
Reproductive hormones play a crucial role in the growth and maintenance of the
mammalian skeleton. Indeed, the biological significance for this hormonal regulation of …

Targeting sex steroid biosynthesis for breast and prostate cancer therapy

M Poutanen, M Hagberg Thulin, P Härkönen - Nature Reviews Cancer, 2023 - nature.com
Sex steroids are major promoters of the growth of breast and prostate cancers. This Review
by Poutanen et al. describes the development of treatments for these cancer types that act to …

Nanoparticles targeting receptors on breast cancer for efficient delivery of chemotherapeutics

S Jahan, ME Karim, EH Chowdhury - Biomedicines, 2021 - mdpi.com
The journey of chemotherapeutic drugs from the site of administration to the site of action is
confronted by several factors including low bioavailability, uneven distribution in major …

Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers

MP Garrido, A Hernandez, M Vega, E Araya… - Frontiers in …, 2023 - frontiersin.org
For many years, luteinizing hormone-releasing hormone or gonadotropin-releasing
hormone (GnRH) analogs have been used to treat androgen or estrogen-dependent tumors …

GnRH analogues as a co-treatment to therapy in women of reproductive age with cancer and fertility preservation

G Valsamakis, K Valtetsiotis, E Charmandari… - International journal of …, 2022 - mdpi.com
In this review, we analyzed existing literature regarding the use of Gonadotropin-releasing
Hormone (GnRH) analogues (agonists, antagonists) as a co-treatment to chemotherapy and …

Gonadotropin-releasing hormone receptor (GnRHR) and hypogonadotropic hypogonadism

P Fanis, V Neocleous, I Papapetrou… - International Journal of …, 2023 - mdpi.com
Human sexual and reproductive development is regulated by the hypothalamic-pituitary-
gonadal (HPG) axis, which is primarily controlled by the gonadotropin-releasing hormone …

Ovarian function suppression with luteinizing hormone-releasing hormone agonists for the treatment of hormone receptor-positive early breast cancer in …

YS Lu, A Wong, HJ Kim - Frontiers in Oncology, 2021 - frontiersin.org
Chemotherapy and endocrine therapies are mainstays of treatment for early and advanced
hormone receptor-positive (HR+) breast cancer. In premenopausal women with HR+ tumors …